Abstract: The invention relates to compositions for treating dandruff comprising compounds that are non-polymeric and/or have a weight average molecular weight of less than about 1000. These compounds, when used at a concentration of about 0.001% or less, inhibit the activity of any Malassezia globosa lipase by at least 50%. The invention also relates to the use of these compounds for inhibiting lipase activity.
Type:
Grant
Filed:
February 19, 2003
Date of Patent:
September 5, 2006
Assignee:
The Procter & Gamble
Inventors:
Joseph Robert Kaczvinsky, Jr., Charles Raymond Degenhardt, Garry Steven Garrett, Charles Winston Saunders, David Joseph Eickhoff, Celeste Dawn Gale, Nancy Lynn Reeder
Abstract: The invention provides a biochemical method for visualizing cellular organelles (such as centrosome) and/or cytoskeletons (such as microtubules) through the use of crystallizing agents (such as tetrazolium salts), a kit containing crystallizing agents adapted for such uses, and to methods particularly for detecting neoplastic cells in a tissue sample, suspension, or a fluid sample by examining the cells for abnormalities of cellular organelles (such as centrosome) and/or cytoskeletons (such as microtubules) in the number and shapes.
Abstract: This invention provides methods of increasing blood flow to tissue in a subject in need thereof, methods of regenerating tissue in a subject, methods of treating diseased tissue in a subject, methods of forming new blood vessels in tissue and new tissue, such as myocardial tissue, in a subject in need thereof, methods of increasing angiogenesis in diseased tissue in a subject, and methods of preventing heart failure in a subject, which methods comprise: a) isolating autologous mononuclear cells from the subject; b) selecting from the isolated autologous mononuclear cells of step (a) lineage negative (Lin?) mononuclear cells; and c) transplanting locally into or adjacent to the tissue an effective amount of the Lin? autologous mononuclear cells, resulting in formation of new blood vessels in the tissue and formation of new tissue.
Abstract: The disclosure describes a method of inhibiting TNF in subjects comprising administering a TNF inhibiting amount of an extract of Eleutherococcus senticosus maxim to a subject. In addition, the present disclosure provides a method of inhibiting TNF in a cell line comprising administering to the cell line a TNF inhibiting amount of an extract from Eleutherococcus senticosus maxim. Finally, the disclosure provides a method of treating a TNF mediated disorder in a subject, comprising administering an effective amount of an extract of Eleutherococcus senticosus maxim to the subject.
Abstract: A water soluble, essentially water-free ubichinon concentrate is described, which contains an emulsifier with an HLB value between 9 and 16, ubichinon Q10, as well as a light oil containing triglyceride. Furthermore, a method for producing the concentrate is described.
Type:
Grant
Filed:
June 29, 2002
Date of Patent:
August 22, 2006
Assignee:
AQUANOVA German Solubilisate Technologies
Abstract: Hydrolyzed collagen type II powder compositions for inducing cartilage formation in an individual, method of preparing the compositions and use of the compositions in treating connective tissue disorder, replenishing skin viscoelasticity. The compositions are administered through an orally ingestible delivery medium for absorption into the gastrointestinal tract. The compositions are administered through a topical delivery medium for absorption into a dermis of the individual.
Abstract: Activated polymeric bicine derivatives such as, as well as conjugates made therewith are disclosed. Methods of making and using the bicine derivatives are also disclosed.
Abstract: Disclosed are neocartilage compositions characterized by having multiple layers of cells, said cells being surrounded by a substantially continuous insoluble glycosaminoglycan and collagen-enriched hyaline extra-cellular matrix, and which neocartilage phospholipids are advantageously enriched in anti-inflammatory n-9 fatty acids, particularly 20:3 n-9 eicosatrienoic or Mead acid. Also disclosed are methods of growing neocartilage in substantially serum-free growth media and methods of producing a conditioned growth media containing compounds effective to enhance neocartilage formation. The neocartilage compositions are useful as implants and as replacement tissue for damaged or defective cartilage and as a model system for studying articular cartilage disease and response to natural and synthetic compounds.
Abstract: A method of treating a human patient with a hypercoagulable state or protein C deficiency, which comprises administering activated Protein C and protein C Zymogen.
Type:
Grant
Filed:
May 14, 2001
Date of Patent:
August 8, 2006
Assignee:
Eli Lilly and Company
Inventors:
Charles Jack Fisher, Brian Paul Barrett, Sau-Chi Betty Yan
Abstract: Disclosed is a composition comprising a substantially purified Cytokine Inhibitory Factor (CIF) having certain characteristics, including the ability to inhibit RNA transcription of the pro-inflammatory cytokines tumor necrosis factor alpha (TNF-?), interleukin-1-beta (IL-1?), and interleukin-2 (IL-2). Also disclosed is a method for substantially purifying the Cytokine Inhibitory Factor and a method for modulating the immune system of an animal using such composition.
Type:
Grant
Filed:
February 11, 2003
Date of Patent:
August 1, 2006
Assignee:
Arkion Life Sciences, LLC
Inventors:
Subramanian Iyer, William L. Johnson, Lance Nguyen, Steven C. Ross, Ruye Xing
Abstract: The present invention provides a method for testing an agent for its potential to inhibit heparanase catalytic activity, comprising the steps of: interacting immobilized heparanase substrate binding protein on a solid support with labeled heparanase substrate to provide immobilized labeled heparanase substrate, interacting a heparanase enzyme solution with the immobilized labeled heparanase substrate in the presence of the agent, and detecting the presence or absence of label in the solution remote from the solid support. The labeled heparanase substrate may be bound to an immobilization bridge which binds to immobilized molecules on a solid support, to provide bridge-immobilized labeled heparanase substrate.
Type:
Grant
Filed:
December 9, 2002
Date of Patent:
July 25, 2006
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Kuo-Sen Huang, Anthony Neri, John L Roberts
Abstract: A method for repairing damaged or diseased urinary tract tissue includes providing a urinary tract tissue graft composition that includes a distal ileal segment of small intestinal submucosa. The distal ileal segment of small intestinal submucosa may be utilized as an unseeded tissue graft composition, or the distal ileal segment of small intestinal submucosa may be positioned in a tissue culture frame, and smooth muscle and urothelial cells isolated from a tissue specimen of a subject and cultured are then seeded upon the distal ileal segment of small intestinal submucosa, thereby forming a urinary tract tissue graft.
Type:
Grant
Filed:
December 6, 2002
Date of Patent:
July 18, 2006
Assignee:
The Board of Regents of the University of Oklahoma
Inventors:
Bradley P. Kropp, Yuan Yuan Zhang, Earl Y. Cheng, Hsueh-Kung Lin, Rick Cowan
Abstract: The present invention refers to a continuous process for gelatines production and chromium recovery from tanned hides and skins shaving, containing trivalent chromium. The claimed process consists in an acid hydrolysis followed by separations of the various products, wherefrom three major components are obtained: gelatine from collagen, tanning chromium salt, used for hides and skins tanning, and the hydrolysing agent. The gelatines obtained can be used as adhesives in various industrial sectors, i.e. from the industry of abrasives to the paper and cardboard industry, to bookbinding, to the industry of dyes and plasters, to the production of matches. The chromium salts obtained can be recovered and reused in the tanning industry; the hydrolysing agent may be recycled.
Abstract: The present invention relates to compounds useful as inhibitors of CAK, compositions thereof. The present invention also relates to methods using the compositions for treating CAK-mediated diseases, such as fungal infections.
Type:
Grant
Filed:
June 6, 2002
Date of Patent:
July 18, 2006
Assignee:
Vertex Pharmaceuticals Incorporated
Inventors:
Brian Ledford, Cameron Stuver Moody, Michael Mullican, Mark Namchuk
Abstract: Product R, a novel therapeutic composition for treating viral infections and stimulating the immune system, comprises a unique peptide having 31 amino acids and another unique peptide having 21 amino acids and connected with an oligo-nucleotide through a diphosphodiester or diphosphodithioate ester linkage. The composition has a light absorption spectrum with typical absorption ratios of 1.998 at 260 nm/280 nm and 1.359 at 260 nm/230 nm.
Type:
Grant
Filed:
July 22, 2002
Date of Patent:
July 11, 2006
Assignee:
Advanced Viral Research Corp.
Inventors:
Bernard Friedland, Shalom Z. Hirschman, Irach B. Taraporewala
Abstract: Compounds of formula I are useful for treating conditions associated with hyperglycemia, especially Type II diabetes. These compounds are useful in stimulating the kinase activity of the insulin receptor, activating the insulin receptor, and stimulating the uptake of glucose. Pharmaceutical compositions comprising the antidiabetic compounds are also disclosed.
Type:
Grant
Filed:
September 6, 2002
Date of Patent:
July 4, 2006
Assignee:
Telik, Inc.
Inventors:
Wayne R. Spevak, Songyuan Shi, Prasad V. V. S. V. Manchem, Michael R. Kozlowski, Steven R. Schow, Robert T. Lum
Abstract: There is provided methods, kits, combinations, and compositions comprising a Aspergillus oryzae protease enzyme, a Bacillus subtilis protease enzyme, and a Aspergillus niger lipase enzyme for treating a digestive disorder in a subject in need thereof. The methods, kits, combinations, and compositions may also be used along with an agent (or combination of agents) for raising the gastric pH, a digestive enzyme useful in enhancing digestive activity, a dietary supplement, or a pharmaceutical agent.
Type:
Grant
Filed:
March 28, 2003
Date of Patent:
June 27, 2006
Assignee:
National Enzyme Company
Inventors:
John G. Davidson, Rohit Medhekar, Jeremy Moore, Ken Paydon, Steve Marr
Abstract: This invention provides supplemented tissue sealants, methods for their production and use thereof. Disclosed are tissue sealants supplemented with at least one cytotoxin or cell proliferation inhibiting composition. The composition may be further supplemented with, for example, one or more antibodies, analgesics, anticoagulants, anti-inflammatory compounds, antimicrobial compositions, cytokines, drugs, growth factors, interferons, hormones, lipids, deminearlized bone or bone morphogenetic proteins, cartilage inducing factors, oligonucleotides polymers, polysaccharides, polypeptides, protease inhibitors, vasoconstrictors or vasodilators, vitamins, minerals, stabilizers and the like.
Type:
Grant
Filed:
June 20, 2003
Date of Patent:
July 18, 2006
Assignee:
American National Red Cross
Inventors:
Martin James MacPhee, William Nash Drohan, Gene Liau, Hernan Nunez, Wilson H. Burgess, Thomas Maciag
Abstract: A psoriasis treatment composition derived from the plant Asphodelus Microcarpus includes 3-methylanthralin, chrysophanol, aloe-emodin, aloe-emodin monoacetate, and/or derivatives thereof. The composition is prepared by extracting a liquid from the Asphodelus Microcarpus root and mixing the liquid with acetic acid. A method of treatment includes applying the composition to an affected area of skin at a frequency sufficient to effect an alleviation of symptoms, typically once per day for 14-56 days.